Ignite Creation Date:
2025-12-25 @ 1:39 AM
Ignite Modification Date:
2025-12-26 @ 1:22 AM
Study NCT ID:
NCT01212094
Status:
TERMINATED
Last Update Posted:
2016-03-28
First Post:
2010-09-29
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Double Blind Combination of Rituximab by Intravenous and Intrathecal Injection Versus Placebo in Patients With Low-Inflammatory Secondary Progressive Multiple Sclerosis (RIVITaLISe)
Sponsor:
National Institute of Neurological Disorders and Stroke (NINDS)
Organization:
Study Modules
Identification Module
Status Module
Sponsor Collaborators Module
Oversight Module
Description Module
Conditions Module
Design Module
Arms Interventions Module
Outcomes Module
Eligibility Module
Contacts Locations Module
References Module
Adverse Events Module
Baseline Characteristics Module
Participant Flow Module